5-ASA Agents
(5-aminosalicylic acid)
These drugs include Sulfasalazine, Mesalazine, and Mesalamine, and are available in the form of oral medications, suppositories, and enemas.
Initially developed as an arthritis treatment, their efficacy for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease was discovered. Since then, they have become widely used as the standard treatment for ulcerative colitis and Crohn's disease.
Features and Limitations:
The exact mechanism of how these drugs are effective for ulcerative colitis or Crohn's disease is not clearly understood, yet they are frequently used in mild, early stages without full knowledge of their mechanism. In cases of early ulcerative colitis, initial intake may induce remission for 1-2 years, but recurrence typically occurs after 1-2 years even with continued use. After recurrence, increasing the dosage often fails to induce remission again.